Revisionist History On Health Care Reform Deal
Executive Summary
President Obama is quite literally writing his legacy on the Affordable Care Act. His account includes a telling discussion of “special interests” that reflects the current state of the relationship between the brand name industry and the Administration – but overlooks the key role that pharma played in helping make health reform happen.
You may also be interested in...
The Campaign Against Drug Pricing: Candidates Can Only Hope Voters React As Strongly As Wall Street
Wall Street remains hypersensitive to threats from Washington or the campaign trail to take action to limit prescription drug pricing. But it is still hard to see why the threat is any greater because the Clinton campaign has a “plan” to address the issue.
Health Care Reform and the Biopharma Sector: A Complete Tactical Victory
The health care reform debate was wild and wooly-but it is hard to imagine a better outcome for the biopharma sector in general and the Pharmaceutical Research & Manufacturers of America in particular. So why isn't anybody celebrating?
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.